EBC-129 demonstrates early activity and manageable safety in patients with heavily pretreated pancreatic cancer, supporting ...

Singapore, 3 June 2025 – The Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and development, has announced the presentation of updated clinical data for ...

Singapore's national platform for drug discovery and development, has announced the presentation of updated clinical data for ...

The expansion cohort for pancreatic ductal adenocarcinoma (PDAC) in the ongoing Phase 1 trial has completed enrolment. Notably, 82% of patients had tumours expressing the antigen at levels considered ...

The novel antibody-drug conjugate EBC-129 has been fast tracked by the FDA for approval in pancreatic ductal adenocarcinoma.

A familiar example is erythropoietin (EPO), which is heavily glycosylated. It is possible to distinguish endogenous from recombinant EPO on the basis of the glycosylation pattern (9).